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Aims: Dietary supplementation with ursolic acid (UA) prevents monocyte dysfunction in diabetic mice
and protects mice against atherosclerosis and loss of renal function. The goal of this study was to
determine the molecular mechanism by which UA prevents monocyte dysfunction induced by metabolic
stress.
Methods and results: Metabolic stress sensitizes or “primes” human THP-1 monocytes and murine
peritoneal macrophages to the chemoattractant MCP-1, converting these cells into a hyper-chemotactic
phenotype. UA protected THP-1 monocytes and peritoneal macrophages against metabolic priming and
prevented their hyper-reactivity to MCP-1. UA blocked the metabolic stress-induced increase in global
protein-S-glutathionylation, a measure of cellular thiol oxidative stress, and normalized actin-S-
glutathionylation. UA also restored MAPK phosphatase-1 (MKP1) protein expression and phosphatase
activity, decreased by metabolic priming, and normalized p38 MAPK activation. Neither metabolic stress
nor UA supplementation altered mRNA or protein levels of glutaredoxin-1, the principal enzyme
responsible for the reduction of mixed disulﬁdes between glutathione and protein thiols in these cells.
However, the induction of Nox4 by metabolic stress, required for metabolic priming, was inhibited by UA
in both THP-1 monocytes and peritoneal macrophages.
Conclusion: UA protects THP-1 monocytes against dysfunction by suppressing metabolic stress-induced
Nox4 expression, thereby preventing the Nox4-dependent dysregulation of redox-sensitive processes,
including actin turnover and MAPK-signaling, two key processes that control monocyte migration and
adhesion. This study provides a novel mechanism for the anti-inﬂammatory and athero- and renopro-
tective properties of UA and suggests that dysfunctional blood monocytes may be primary targets of UA
and related compounds.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Ursolic acid (UA), a cyclic triterpenoid, is an anti-inﬂammatory
phytochemical widely distributed within the plant kingdom and
found in medicinal and traditional herbs, as well as a large number
of fruits [1–3]. Initially studied for its anti-cancer properties,
UA induces apoptosis in cancer cells and reduces tumor growth
[1]. More recently, UA0s anti-inﬂammatory properties have been
studied in the context of metabolic disorders and UA is emerging
as a potential preventative and therapeutic agent for metabolic
diseases. UA has been reported to affect a multitude of enzymes
involved in inﬂammatory processes, including, but not limited to,
cyclooxygenase 2 (COX2) [4], NF-ĸB [5,6], and nitric oxide synthase
(NOS) [4,7,8]. In disease-speciﬁc animal models, UA administration
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was shown to protect and preserve the functionality of various
organs including liver [9,10], kidney [11–13], pancreas [14], skele-
tal muscle [15], and brain [16,17]. UA showed beneﬁcial effects in
rodent models of hypertension [18], obesity [15], and diabetes
[13,19]. We recently showed that UA protects diabetic mice against
diabetic complications, including atherosclerosis [13]. However,
the molecular mechanisms underlying these beneﬁcial properties
of UA are largely unknown.
Atherosclerosis is characterized by chronic inﬁltration of
inﬂammatory cells, particularly monocytes, into the subendothe-
lial space in the vascular wall [20]. Chemoattractant-stimulated
monocyte recruitment and transmigration into the vessel wall
dominate all stages of atherosclerosis and play a fundamental role
in the initiation and progression of atherosclerotic lesions. Within
lesions, monocyte-derived macrophages orchestrate the continu-
ous inﬁltration of inﬂammatory cells and the remodeling of the
vessel wall, thereby maintaining a chronic state of inﬂammation
[20]. Chronic inﬂammation and oxidative stress are hallmark
features of metabolic diseases, including atherosclerosis, and drive
disease progression [21]. We recently reported that metabolic
stress transforms monocytes into a proatherogenic phenotype,
resulting in their hyper-responsiveness to chemoattractants,
a process we coined monocyte priming [22]. Monocyte priming
correlates with both increased monocyte chemotaxis and recruit-
ment in vivo and accelerated atherosclerotic lesion formation,
suggesting that monocyte priming by metabolic stress may be a
novel, fundamental mechanism underlying atherosclerosis and
other chronic inﬂammatory diseases [22]. We demonstrated that
monocyte priming is mediated by NADPH oxidase 4 (Nox4)-
induced thiol oxidative stress and the subsequent dysregulation
of redox sensitive signaling pathways [22–24]. We went on to
show that Nox4 induction was both necessary and sufﬁcient to
promote metabolic priming in monocytes [22].
Nox4 is one among the seven members of the NAPDH oxidase
family whose function is to transport electrons across a membrane
to produce reactive oxygen species (ROS) [25]. Unlike the majority
of Nox proteins, which produce superoxide, Nox4 appears to
primarily produce hydrogen peroxide (H2O2) [26–28]. In response
to physiological stimuli, Nox4 generates H2O2 and activates signal-
ing pathways, such as insulin [29] and epidermal growth factor
signaling [30], through the oxidation of speciﬁc protein thiols.
Protein thiols can undergo oxidation to various oxidation products,
including S-glutathionylated thiols, i.e., mixed disulﬁde bonds
between protein thiols and glutathione [31]. Protein-S-glutathio-
nylation is an important post-translational modiﬁcation in redox
signaling and can inhibit or activate protein function [32,33], and
even target proteins for degradation [23,34]. We recently found
that increased actin-S-glutathionylation in response to metabolic
stress increases actin turnover in monocytes, which appears to
contribute to enhanced monocyte adhesion to endothelium and
accelerated monocyte migration and tissue inﬁltration [22,23].
Furthermore, we found that in response to metabolic stress,
mitogen-activated protein kinase phosphatase 1 (MKP-1) is glu-
tathionylated, targeting MKP-1 for proteasomal degradation. MKP-
1 S-glutathionylation results in the hyperactivation of MAPK
signaling pathways that control monocyte adhesion and migration
[22–24].
Current prevention strategies and treatments for metabolic and
chronic inﬂammatory diseases focus mainly on reducing or pre-
venting inﬂammation and oxidative stress. Due to their relatively
low cost and low toxicity, phytochemicals may provide an attrac-
tive alternative to current approaches in disease prevention and
management. A number of compounds have shown promise for
reducing or even reversing symptoms of diseases characterized
by chronic inﬂammation [35–37]. We recently reported, in a
mouse model of diabetic complications, that dietary UA reduces
monocyte dysfunction and protects against accelerated athero-
sclerosis and kidney injury [13], but the underlying mechanisms
are unknown. In this study, we provide evidence that UA protects
blood monocytes from metabolic priming and dysfunction by
inhibiting the induction of Nox4 and reducing cellular protein-S-
glutathionylation, speciﬁcally, S-glutathionylation of two impor-
tant redox signaling proteins essential for monocyte adhesion and
migration, actin and MKP-1. Based on these data, we propose a
novel mechanism of action that may explain many of the anti-
inﬂammatory properties of UA. Our study highlights the thera-
peutic potential of UA and related compounds.
Materials and methods
Chemicals and reagents
Unless stated otherwise, chemicals were purchased from Sigma-
Aldrich, St. Louis, MO, cell culture reagents from Gibcos Invitrogen,
Grand Island, NY, and all primers and supplies for qPCR were
purchased from Invitrogen, Grand Island, NY.
Monocyte priming
Monocyte priming was induced as described previously [22].
Brieﬂy, human THP-1 monocytes (ATCC, Manassas, VA) at 1–
2106 cells/ml were cultured at 37 1C for 20 h in RPMI-1640
(Hyclone and Cellgros) containing, 10% fetal bovine serum (FBS),
5.5 mM D-glucose, 2% Glutamax, 1% sodium pyruvate (Cellgros),
1% penicillin/streptomycin (Cellgros), 1% HEPES, 0.1% β-2-mercap-
toethanol, and supplemented with either phosphate buffered
saline (PBS) or freshly isolated native human LDL (100 mg/ml in
PBS) plus D-glucose (high glucose, 20 mM). L-glucose does not
increase monocyte priming [22]. For selected experiments, peri-
toneal macrophages were collected from C57BL/6 mice by perito-
neal lavage and puriﬁed by negative selection using antibody-
coated magnetic beads (Dynabeadss mouse pan B (B220) and
Dynabeadss mouse pan T (Thy 1.2)). This procedure routinely
increased the macrophage content of the isolate from approxi-
mately 40% CD68-positive cells to greater than 95% CD68 positive
cells. Puriﬁed macrophages were cultured in Teﬂon bags under
non-adherent conditions [38], and primed for 24 h in complete
RPMI-1640 medium supplemented with human LDL (100 mg/ml in
PBS) plus D-glucose (20 mM, HG)
LDL isolation
LDL was isolated by KBr-gradient ultracentrifugation from pooled
plasma from healthy blood donors and puriﬁed by gel-ﬁltration
chromatography, ﬁlter-sterilized and characterized as described pre-
viously [39,40].
Monocyte chemotaxis assay
THP-1 monocytes or puriﬁed peritoneal macrophages were
primed with HGþLDL for 20–24 h in the presence of either vehicle
(dimethyl sulfoxide, DMSO, r0.1%) or UA, then loaded into the
upper wells of a 48-well modiﬁed Boyden chamber (NeuroProbe,
Gaithersburg, MD). The lower wells contained either vehicle or
2 nM MCP-1 (R&D Systems, Minneapolis, MN). A 5 mm polyvinyl
pyrrolidone-free polycarbonate ﬁlter membrane was layered
between the upper and lower chambers, and the chamber was
incubated for 2 h for THP-1 monocytes or 3 h for peritoneal
macrophages at 37 1C and 5% CO2. The membrane was washed
and cells removed from the upper side of the ﬁlter. Transmigrated
cells were stained with Diff-Quiks Set (Dade Behring, Newark, DE)
and counted in four–ﬁve separate high power ﬁelds at 400
magniﬁcation under a light microscope.
S.L. Ullevig et al. / Redox Biology 2 (2014) 259–266260
Western blot analysis
Cells were washed with ice-cold PBS and lysed on ice in RIPA
lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Nonidet
P-40, 0.1% SDS, 0.5% sodium deoxycholate) with protease inhibitor
and/or phosphatase inhibitors. Aliquots with equal amounts of
protein were loaded and separated on an 8% or 10% SDS-PAGE gel.
Proteins were transferred to polyvinylidene diﬂuoride membranes
(PVDF, Millipore, Billerica, MA) and probed using speciﬁc anti-
bodies. The following antibodies were used: Nox4 [41] (available
from Epitomics, 3174-1, Burlingame, CA), Anti-glutathione anti-
body: Millipore (MAB5310, Billerica, MA), p38/p38-phospho:
Cell Signaling (9212S and 9211S, respectively, Danvers, MA) and
MKP-1: Santa Cruz (SC-370, Santa Cruz, CA), actin: Santa Cruz
(SC1615), Grx-1: R&D systems (AF3399, Minneapolis, MN).
Bands were detected by chemiluminescence on a KODAK Image
Station 4000MM (Carestream, Rochester, NY). To control for
sample loading, blots were subsequently stripped and re-probed
for total p38 or actin.
Reverse transcription quantitative polymerase chain reaction
(RT-qPCR)
Brieﬂy, total RNA was extracted using the PureLink RNA Mini
Kit and quantiﬁed using a NanoDrop spectrophotometer (Thermo-
Scientiﬁc, Rockford, IL). Total RNA (1 μg) was synthesized into
cDNA using the Maxima First Strand cDNA Synthesis Kit (Thermo-
Scientiﬁc, Asheville, NC). Taqman probes were used for all genes
(Grx-1: Hs00829752_g1, Nox2: Hs01553393_m1, GAPDH:
Hs99999905_m1) using the cycling conditions described by the
manufacturer. No ampliﬁcation was detected in no-template con-
trol wells. Gene expression levels were normalized to GAPDH and
mRNA fold-change relative to control wells was calculated using
the ΔΔCt method [42]. Four biological replicates and three
technical replicates were performed.
MKP-1 activity assays
MKP-1 activity was determined with a modiﬁcation of the
commercially available MalachiteGreen-based PTP assay (Milli-
pore, Billerica, MA). Brieﬂy, to assess MKP-1-speciﬁc PTP activity,
lysates were analyzed both in the absence and presence of 40 mM
sanguinarine (SG), a speciﬁc inhibitor of MKP-1 (34). SG-sensitive
PTP activity was attributed to MKP-1. Brieﬂy, assays were initiated
by adding 10 ml of phosphotyrosine peptide substrate to cell
extracts (2 mg protein) diluted in 20 mM Tris–HCl (pH 7.5),
150 mM NaCl, 1% NP-40 and warmed to 30 1C. The reaction was
stopped after 10 min. MKP-1 activity was assayed spectrophoto-
metrically as the amount of inorganic phosphate released using a
VersaMax (Molecular Devices, Sunnyvale, CA). Phosphate released
by MKP-1 was quantiﬁed from a standard curve prepared with
known amounts of KH2PO4.
Statistics
Data were analyzed using ANOVA (SigmaStat, Systat Software,
San Jose, CA). Data were tested for use of parametric or nonpara-
metric post hoc analysis, and multiple comparisons were per-
formed by using the Least Signiﬁcant Difference method. All data
are presented as mean7SE of at least 3 independent experiments
unless stated otherwise. Results were considered statistically
signiﬁcant at the Po0.05 level.
Results
Ursolic acid protects monocytes against metabolic priming
Previously, we showed that UA inhibits the priming effect of
oxidative stress, i.e. extracellular H2O2, on monocyte chemotaxis
with a median inhibitory concentration (IC50) of 0.45 mM [13].
We also reported that THP-1 monocytes exposed to metabolic
stress, i.e. high glucose (HG, 25 mM) plus human LDL (100 mg/ml),
shows a similar hypersensitivity to MCP-1 as oxidatively stressed
THP-1 monocytes [22]. We therefore tested if UA also protected
THP-1 monocytes against chemokine hypersensitivity and dys-
function induced by metabolic stress. UA prevented monocyte
priming in a dose-dependent manner (Fig. 1A and B). In the
presence of 3 mM UA, monocyte priming was reduced by 83%,
and at 10 mM, normal chemotactic responses were restored (Fig. 1A
and B). In agreement with our previous studies with H2O2-treated
THP-1 monocytes [13], UA inhibited monocyte priming with an
IC50 of 0.4 mM, indicating this inhibition may occur through a
similar mechanism. Importantly, UA treatment alone did not affect
MCP-1-stimulated chemotaxis in unprimed monocytes (Fig. 1C),
suggesting that UA targets speciﬁc mechanisms or signaling path-
ways involved in the dysregulation of monocyte migration, but not
chemotaxis per se.
To conﬁrm that the protective effects of UA were not limited to
THP-1 monocytes, we repeated these experiments in puriﬁed
peritoneal macrophages isolated from C57BL/6 mice. Murine
peritoneal macrophages exposed to metabolic stress (HGþLDL)
ex vivo showed a similar hyper-sensitization to MCP-1-induced
chemotaxis as primed THP-1 cells (Fig. 1B and D). Importantly,
when UA was present during metabolic priming by HGþLDL, the
increased chemotactic responses of peritoneal macrophages were
prevented (Fig. 1D).
Ursolic acid reduces both total protein-S-glutathionylation and actin-
S-glutathionylation induced by metabolic stress
The dysregulation of monocyte chemotactic responses by
metabolic stress (HGþLDL) is mediated by increased cellular
protein-S-glutathionylation, including the increased S-glutathio-
nylation of actin [22,24]. We now found that UA dose-dependently
inhibited actin-S-glutathionylation induced by metabolic stress
(Fig. 2A and B). At 3 mM UA, hyper-S-glutathionylation of actin
was reduced by 75% (Fig. 2C). At the same concentration, UA also
reduced by 73% total cellular protein-S-glutathionylation induced
by metabolic priming (Fig. 2D), suggesting that UA targets a
protein or a pathway responsible for mediating metabolic stress-
induced S-glutathionylation of multiple proteins. At 10 mM UA,
levels of actin S-glutathionylation were completely normalized to
levels seen in healthy control cells (Fig. 2A).
Ursolic acid does not alter Grx1 mRNA or protein levels
Glutaredoxin-1 (Grx1) is the primary cytosolic enzyme that
speciﬁcally reduces S-glutathionylated proteins in THP-1 mono-
cytes [43]. Overexpression of Grx1 in THP-1 monocytes reduces
S-glutathionylated proteins and prevents the conversion of mono-
cytes into the proatherogenic primed phenotype [22]. To deter-
mine whether Grx1 expression was a target of UA, we measured
Grx1 mRNA by quantitative PCR and protein expression by
Western Blot. Surprisingly, neither Grx1 mRNA nor protein expres-
sion was signiﬁcantly altered by UA in either primed or unprimed
THP-1 monocytes (Supplementary Fig. 1A and B). In unprimed
THP-1 monocytes, UA treatment resulted in an increase in Grx1
protein expression (40% increase), but the difference was not
statistically signiﬁcant (P¼0.073). The inhibitory effect of UA on
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protein-S-glutathionylation in metabolically primed monocytes
can therefore not be explained by induction of Grx1.
Ursolic acid rescues MAPK phosphatase-1 protein degradation and
activity
MAPK phosphatase-1 (MKP-1) is a redox sensitive phosphatase
that regulates the phosphorylation and activity of p38 and Erk
proteins [44–46]. Metabolic priming of monocytes promotes MKP-
1-S-glutathionylation, resulting in MKP-1 inactivation and subse-
quent proteasomal degradation [23]. We therefore examined
whether UA could protect MKP-1 protein expression and activity
in metabolically stressed THP-1 monocytes. At 3 mM, UA prevented
the metabolic stress-induced degradation of MPK-1 (Fig. 3A and B)
and fully rescued MKP-1 activity in metabolically primed THP-1
monocytes (Fig. 3C).
Loss of MKP-1 activity leads to the hyperactivation of p38,
as measured by the phosphorylation of p38, both in resting THP-1
monocytes and in response to MCP-1 stimulation [23]. We there-
fore determined if UA also prevents the hyperactivation of p38 in
metabolically primed THP-1 monocytes. UA normalized p38 phos-
phorylation to levels found in healthy control cells (Fig. 3D).
These data suggest that, under conditions of metabolic stress, UA
protects MAPK signaling pathways that control monocyte adhe-
sion and migration, by preventing MKP-1-S-glutathionylation,
inactivation and degradation.
Ursolic acid reduces Nox4 protein expression
Nox4-derived H2O2 mediates metabolic stress-induced mono-
cyte priming and the S-glutathionylation of actin and MKP-1
induced by metabolic stress [22]. Since UA prevented actin-S-
glutathionylation induced by metabolic stress and rescued MKP-1
degradation and activity without altering Grx-1 expression, we
next investigated whether UA is able to prevent the induction of
Nox4 we observed in metabolically-primed THP-1 monocytes.
Indeed, we found that at 3 mM, UA inhibited the metabolic
stress-induced increase in Nox4 protein levels by 77% (Fig. 4A,
Supplementary Fig. 2). UA also blocked the induction of Nox4 in
metabolically stressed mouse peritoneal macrophages (Fig. 4B).
Oleanolic acid (OA) is a structural isomer of UA that differs only
in the position of one methyl group. Despite its structural
similarities to UA, OA is 3.5-fold less potent than UA in inhibiting
accelerated monocyte chemotaxis induced by metabolic stress
(IC50 of OA¼1.4 mM, data not shown, versus an IC50¼0.4 mM for
UA, Fig. 1A). Here we show that OA was also signiﬁcantly less
potent at blocking metabolic-stress-stimulated Nox4 induction.
At 3 mM, OA only inhibits Nox4 induction by 30%, compared to 77%
inhibition by UA at the same concentration (Fig. 4A). Both UA and
its analog OA appear to protect THP-1 monocytes against meta-
bolic priming by blocking Nox4 protein expression induced by
metabolic stress.
Nox2 is the primary Nox isoform found in monocytes and
macrophages and is a potential source of ROS that could promote
protein-S-glutathionylation and contribute to the effects of
Fig. 1. UA attenuates metabolic stress-induced acceleration of monocyte chemotaxis in response to MCP-1. (A) THP-1 cells cultured in RPMI 1640 medium (5 mM glucose,
10% FBS) were treated for 20 h with HG (20 mM D-glucose) and native LDL (100 mg/ml) in the presence of 0, 0.3, 1.0, 3.0 or 10 mM UA or vehicle (DMSO).
The supernatant was removed and cells were resuspended in 0.1% FBS-containing RPMI medium. Cells were then transferred into a multi-well Boyden chamber and
stimulated with 2 nM MCP-1 for 2 h. Migrated cells were counted in 4 high-power ﬁelds (HPF) per well, 4 wells for each condition. Data were normalized to the accelerating
effect of metabolic stress on chemotaxis (“100%”), i.e., values obtained for HGþLDL-primed THP-1 monocytes stimulated with MCP-1 minus values obtained from unprimed
THP-1 monocytes stimulated with MCP-1 (“0%”;dotted line). Results are shown as mean from 5 independent experiments7SE; #versus 100% acceleration, P¼0.038
(0.3 mM), P¼0.002 (1, 3 mM), Po0.001 (10 mM). (B) Chemotaxis was assayed as in (A). The graph depicts the fold change induced by HGþLDL in MCP-1-stimulated
chemotaxis (red bar) and by HGþLDLþ3 mM UA (green bar) versus unprimed, MCP-1 stimulated control cells (white bar). n¼5, mean7SE. nversus unprimed control (no
metabolic stress), Po0.001; #versus HGþLDL, P¼0.002, (C) Chemotaxis was assessed in unprimed cells treated with either vehicle (open bar) or UA (gray bar) as described
in (A). Values represent means of 4 HPF counts for control cells, and cells treated with vehicle or 10 mM UA; mean7SE; n¼4, P¼0.712. (D) Chemotaxis was assessed in
unprimed mouse peritoneal macrophages (open bars), or macrophages that were metabolically primed (red bars) or metabolically primed in the presence of UA (green bar).
nversus unprimed control macrophages (no metabolic stress), P¼0.002; #versus HGþLDL, P¼0.016; nnversus unprimed control macrophages, P¼0.30.
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Fig. 2. UA reduces actin- and total-S-glutathionylation induced by metabolic stress. THP-1 monocytes in RPMI 1640 medium (5 mM glucose, 10% FBS) were treated with 0.3,
1, 3, 10 mM UA or vehicle. HG (20 mM glucose) plus native LDL (100 mg/ml) was present for 20 h where indicated. Cells were lysed in the lysis buffer containing 10 mM NEM.
Actin- and protein-S-glutathionylation was assessed by Western blot analysis using the anti-glutathione antibody. Western Blot data for actin-S-glutathionylation is
summarized in A–C. (A) A representative Western Blot is shown. (B) Quantitation by Western blot analysis assessed using an anti-glutathione antibody is shown of actin-S-
glutathionylation in response to increasing doses of UA. n¼4, mean7SE. # versus 100% actin-S-glutathionylation, P¼0.004 (1 mM), P¼0.003 (3 mM), Pr0.001 (10 mM).
(C) Quantitative data for actin-S-glutathionylation and the effects of 3 mM UA. Data is represented as fold change induced by HGþLDL (red bar) and HGþLDLþ 3 mM UA
(green bar) versus unprimed control cells (white bar). n¼3, mean7SE; nversus Control, P¼0.006, # versus HGþLDL, P¼0.022. (D) Total protein-S-glutathionylation was
determined byWestern blot and the density of the entire lane was measured and normalized to actin. Total protein-S-glutathionylation is represented as fold change induced
by HGþLDL (red bar) and HGþLDLþ3 mM UA (green bar) versus unprimed control cells (white bar). n¼4, mean7SE, nversus control, Po0.001, #versus HGþLDL, P¼0.003.
Fig. 3. UA rescues MKP-1 protein expression and activity in metabolically primed THP-1 monocytes. THP-1 cells were treated for 20 h with 3 mM UA or vehicle control in the
presence of HGþLDL. (A) Representative Western blot MKP-1 protein levels. (B) Quantitation of Western blot analysis. Data was normalized to actin and is shown as mean7SE of
3 independent experiments. nversus unprimed control cells (no metabolic stress), P¼0.017; #versus HGþLDL primed cells, P¼0.012. (C) MKP-1 phosphatase activity was assessed
using a modiﬁcation of the commercially available Malachite Green-based PTP assay as described under Material and Methods. n¼3, nversus unprimed control cells (no metabolic
stress), P¼0.002; #versus HGþLDL, Po0.001. (D) Phospho p38 was measured by Western blot analysis as described in “Material and methods” section. Data was normalized to
total p38. n¼3, mean7SE; nversus unprimed control cells (open bar), P¼0.003, #versus HGþLDL (red bar), Po0.001, HGþLDLþ3 mM UA (green bar).
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metabolic stress on monocyte chemotaxis. However, we found no
induction of Nox2 in metabolically primed THP-1 monocytes nor
did UA have any effect on Nox2 mRNA levels in either control or
metabolically primed THP-1 monocytes (Supplementary Fig. 3).
This ﬁnding conﬁrms our previous report that Nox2 does not
mediate thiol oxidative stress and monocyte dysfunction induced
by metabolic stress [22].
Discussion
We recently reported that metabolic stress, in vitro and in vivo,
results in the hyper-sensitization of monocytes to chemoattrac-
tants, a process we termed monocyte priming. Metabolic priming
of monocytes results in the increased adhesion, accelerated
chemotaxis and increase recruitment of monocyte-derived macro-
phages in response to chemokines [22–24]. Not only may mono-
cyte priming be involved in atherogenesis, but it also appears to
contribute to the acceleration of atherosclerosis and renal injury
associated with diabetes [22]. Dietary supplementation with UA
prevented the accumulation of inﬂammatory monocytes in the
blood of diabetic mice, reduced in vivo monocyte chemotactic
activity in these mice, improved renal function, and decreased
both plaque size, and macrophage content in atherosclerotic
lesions in these mice [13]. These studies suggested that UA may
directly target blood monocytes and protect them from metabolic
stress-induced priming, preventing them from converting into a
proatherogenic, hyper-inﬂammatory phenotype. The goal of this
study was to determine the molecular mechanisms through which
UA prevents monocyte dysfunction and thus may exert its anti-
atherogenic and renoprotective properties.
Monocyte priming by metabolic stress involves the early
induction of Nox4, Nox4-dependent thiol oxidation and the sub-
sequent, persistent protein-S-glutathionylation of a large number
of proteins, processes which all contribute to the accelerated
chemotactic responses to chemokine stimulation (Fig. 5) [22].
Here we report that UA blocked these effects of metabolic stress
on both human THP-1 monocytes and murine peritoneal macro-
phages. Since Nox4 induction is both necessary for metabolic
priming and sufﬁcient to induce metabolic priming in monocytes
Fig. 4. UA prevents Nox4 protein induction by metabolic stress. (A) THP-1 monocytes cultured in RPMI 1640 medium (5 mM glucose, 10% FBS) were treated with 3 mM UA,
3 mM OA, or vehicle for 1 h prior to the addition of glucose (20 mM HG) plus native LDL (100 mg/ml) for an additional 20 h. Nox4 protein expression was determined by
Western blot analysis as described under “Material and methods” section. Data was normalized to actin levels. Results are shown as mean7SE of 3–4 independent
experiments. nversus unprimed control (open bars, no metabolic stress), Po0.001; #versus HGþLDL primed cells (red bar), Po0.001; nnversus HGþLDL, P¼0.081.
HGþLDLþ3 mM UA (green bar) and HGþLDLþ3 mM OA (yellow bar). (B) Mouse peritoneal macrophages treated ex vivo with HGþLDL, with or without 3 mM UA, for 24 h.
Nox4 protein expression was determined as in (A). n¼3, nversus unprimed control (open bars, no metabolic stress), P¼0.002; #versus HGþLDL primed cells (red bar),
P¼0.008.
Fig. 5. Hypothetical model for the mechanism of action of UA in metabolically primed monocytes. (A) The effects of metabolic stress are indicated by red arrows. Metabolic
stress (HGþLDL) increases Nox4 protein expression and Nox4-derived H2O2 formation [22]. We hypothesize that Nox4-derived H2O2 promotes increases in total cellular
protein-S-glutathionylation and the S-glutathionylation of actin and MKP-1, two proteins important in monocyte migration and adhesion [22–24]. The increase in actin and
MKP-1 S-glutathionylation results in increased monocyte chemotaxis and accelerated macrophage recruitment [22], rate-limiting steps in the development of
atherosclerosis. (B) The effects of ursolic acid (UA) are indicated by green arrows. In the presence of ursolic acid, the metabolic stress-induced induction of Nox4 protein
expression and subsequent S-glutathionylation of MKP-1 and actin are prevented. Normal monocyte migration is restored in the presence of ursolic acid.
S.L. Ullevig et al. / Redox Biology 2 (2014) 259–266264
[22], we hypothesized that UA targets Nox4 expression in meta-
bolically primed monocytes. Indeed, we found that UA prevented
the induction of Nox4 in metabolically primed monocytes at
concentrations that also blocked hyper-S-glutathionylation of
actin, MKP-1 S-glutathionylation and degradation, and the exag-
gerated chemotactic response of primed monocytes to MCP-1
(Fig. 5). Yet, Nox2 expression levels were not affected by UA,
suggesting the inhibitory effect of UA is speciﬁc for Nox4 and
appears to occur at the transcriptional or translational level, rather
than by inhibiting Nox4 activity itself, although further studies are
needed to conﬁrm this hypothesis. Our ﬁndings are in agreement
with a previous study reporting that UA treatment of a human
endothelial cell line reduces Nox4 expression [8].
Based on mapped consensus sequences in the Nox4 promoter
region, Nox4 transcription may be under the control of several
transcription factors, including NF-kB, peroxisome proliferator-
activated receptors (PPARs), members of the O subclass of fork-
head transcription factors (FOXO), and SMA/MAD related tran-
scription factor (SMAD) [47]. It is possible that UA regulates Nox4
transcription. Many of UA’s anti-inﬂammatory and anti-tumor
effects have been shown to coincide with reduced NF-kB expres-
sion and activation [5,6]. In a liver cell line, UA was reported to
increase both PPARα expression and binding of activated PPARα to
peroxisome proliferator response elements (PPRE), thereby acti-
vating gene transcription [48]. Collectively, these data suggest that
UA may prevent Nox4 induction at the transcriptional level by
blocking the binding of transcription factors, such as NF-kB, to the
Nox4 promoter.
Alternatively, UA may suppress Nox4 expression by inhibiting
translational events. Nox4 translation was shown to be regulated
by serum [49] and microRNAs [50], including miR-25c [51], miR-
145ac [52], miR-23b[53]. It is unclear at this point, whether UA
affects any of these translational events, although in a glioblas-
toma cell line, UA was shown to suppress miR-21 [54]. One
regulator of protein synthesis activated by high glucose levels is
mTOR. Interestingly, mTOR was reported to be inhibited by UA
[55]. This ﬁnding suggests that inhibition of mTOR may be another
plausible mechanism to explain UA0s ability to suppress Nox4
expression induced by metabolic stress. Indeed, we found that the
mTOR inhibitor rapamycin reduced Nox4 protein expression in
unprimed THP-1 monocytes (unpublished data), suggesting that
UA may prevent Nox4 induction and monocyte priming via an
mTOR-dependent pathway.
While the exact mechanisms through which UA prevents meta-
bolic stress-induced Nox4 expression remains to be elucidated, the
ability of UA to block Nox4 induction, and thus metabolic priming in
monocytes, may explain UA’s potent anti-inﬂammatory properties
in vivo, including its ability to improve kidney function and block
atherosclerotic lesion formation in diabetic mice [13]. It is important
to note, that the dosages of UA at which we observed protective
effects in cultured human THP-1 monocytes and murine peritoneal
macrophages (0.3–3 mM) are well within the range of the UA
plasma concentrations reported in published studies (0.1–2.4 mM)
[56,57]. In our hands, diabetic mice fed a diet enriched with 0.2%
UA, a dose that suppresses atherosclerotic lesion formation and
renal injury, showed UA plasma concentrations that ranged from
0.1 to 0.3 mM (unpublished results), indicating that the UA concen-
trations we used in our cell culture experiments and the observed
beneﬁts are physiologically relevant.
In summary, we found that UA prevents metabolic stress-
induced monocyte priming by blocking Nox4 induction, thereby
inhibiting the dysregulation of two important thiol redox-sensitive
signaling mechanisms involved in monocyte adhesion and migra-
tion, i.e. actin turnover and MAPK signaling (Fig. 5). This study
provides a novel mechanism of action for UA which may explain
its anti-inﬂammatory and anti-atherogenic properties.
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